A systematic review of the literature about the causal relationship between priapism and adrenergic a-blockers used for the treatment of lower urinary tract symptoms (LUTS) and arterial hypertension was accomplished. While opportunely describing a case of tamsulosin-induced priapism, we reviewed the literature using MEDLINE, COCHRANE and LILACS libraries, selecting all the articles until the present time addressing the association between priapism and a-blockers. Our patient was a healthy 32-year-old man who reported LUTS. His prostate was firm and moderately enlarged on digital rectal examination, measuring 30 grams on transabdominal ultrasound. Empirical treatment with tamsulosin was initiated and he developed priapism the day after the first dose of the drug. Erection was reverted by aspiration of the corpora and intracavernosal injection of adrenaline. Despite the late presentation (40 h of erection), he had no ED on follow-up. In the systematic review, among 2157 articles on priapism, only 13 similar cases reported a-blockers as the etiology of priapism. Therefore, adrenergic a-blockers are effective and safe drugs, with few serious adverse reactions. Nevertheless the association with priapism is well documented and related to substantial morbidity, this is an infrequent event and should not preclude their use, considering that the patient be sufficiently informed.
Introduction
Adrenergic a-blockers were developed primarily for blood pressure control. Subsequently to comprehension of their relaxing effect on prostatic stroma and capsule, they were incorporated into Urological practice and became the mainstay of the medical treatment of lower urinary tract symptoms (LUTS) of prostatic origin. 1 The a1-receptor is the most prevalent type in the urinary tract, and three subtypes exist: a, b and d. In the prostate, the most prevalent is subtype a1a, whereas subtype a1b predominates in the cardiovascular system. [2] [3] [4] It is the concomitant antagonism of these a1b receptors, prominently by non-uroselective drugs, that produces the most common adverse reactions observed in clinical practice, which are predominantly cardiovascular and include dizziness, orthostatic hypotension and syncope. 5, 6 Doxazosin, prazosin and terazosin are non-uroselective, responsible for most of the side effects related to this class of drugs. [1] [2] [3] [4] Tamsulosin is the first uroselective antagonist, and fewer adverse reactions in comparison with the other a-blockers have been observed with this medication. 1, 5 Priapism is also described as an adverse reaction, but its occurrence is rare and reported essentially in the context of older, non-uroselective drugs, applied for the treatment of hypertension in higher doses than those used for LUTS treatment. 7 Possibly because of this infrequency, patients may be inadequately informed about the risk of priapism, leading to delayed medical care with its incapacitating consequences.
The purpose of this article is to examine the association between priapism and a-blockers, driving attention of urologists to this commonly overlooked and ominous adverse effect.
Materials and methods
A case of priapism caused by tamsulosin is reported, and a systematical review addressing the causal relationship between a-blockers and priapism was conducted in the MEDLINE, COCHRANE and LILACS database, using the key words priapism, priapism and a-blockers, a-blockers and adverse effects, without time limit. The abstracts of the retrieved articles were examined by the authors and those that did not address specifically the association of priapism and a-blockers were discarded.
Main outcome measures
Articles found were examined to delineate the pathogenesis, frequency, clinical characteristics and outcomes, as well as treatment strategies adopted in the treatment of patients with priapism induced by a-blockers.
Results
Our interest was driven to this issue after we managed a 32 year-old-man who complained of urinary urgency and frequency. His prostate was firm and moderately enlarged on digital rectal examination. Urine cultures and urinalysis were normal. A transabdominal ultrasonography revealed a prostate of 30 g, thin bladder walls and absence of significant postvoid residual volume. He was started on tamsulosin empirically and developed a painful, persistent erection the morning after the first nocturnal dose of the drug. Presentation to hospital, however, occurred only after 40 h of erection. Other causes of priapism were unlikely, as medical evaluation was not demonstrative of associated medical conditions, previous episodes of painful erections, genital trauma or concomitant consumption of other drugs, alcohol or illegal substances.
The priapism was treated with puncture, aspiration and irrigation of the corpora cavernosa with a 1:1000 adrenaline solution, with reversion of the prolonged erection. On follow-up, he did well, recovering sexual function completely (rigid erections started 10 days later) and presenting no recurrence following discontinuation of the drug.
The literature search yielded 2157 references, of which 17 cited the association and only 13 indeed described clinical cases of priapism caused by ablockers. The first report dates to 1979 and the last to 2009. 7, 8 The selected articles were analyzed, and a table was created summarizing patient characteristics, type of drug, dosage, management and clinical outcome of each one (Table 1) .
Discussion
The a-blockers participate in erection physiology by blocking sympathetic stimuli responsible for penile detumescence. This is the proposed mechanism for induction of priapism by this class of drugs. 9 Phentolamine, a non-selective a-blocker, has been used since 1985 as an intracavernosal solution that also contained prostaglandin or papaverin for induction or facilitation of erection, but is not prescribed for LUTS treatment. 10 More recently, an oral route preparation of phentolamine mesylate was developed and is effective in mild or moderate cases of ED. 11, 12 Among the 17 articles found, doxazosin, prazosin, alfuzosin, terazosin and even tamsulosin were implicated. Zorgniotti analysis of oral phentolamine in the treatment of ED did not observe the occurrence of prolonged erection despite the efficacy of the medication in facilitating erection. 13 Other prospective trials were conducted, but there were no reports of priapism related to phentolamine. 11, 12 In medical literature, prazosin is the a-blocker more frequently associated with priapism, possibly because of its widespread used in the past as an antihypertensive drug in doses higher than those prescribed in the urological practice ( Table 1 ). The occurrence of priapism associated with tamsulosin is even rarer and to date only two cases were reported. 14, 15 There is also a third case of tamsulosin associated with partial priapism, in which a proximal corpora thrombosis was identified. 8 The case we report is the fourth published. In a recent multicenter trial conducted to study the influence of the drug on sexual function, daily tamsulosin (0.4 mg) was compared with placebo and alfuzosin (7.5 mg), but priapism did not occur in any of the groups, substantiating the low incidence of this adverse event. 1 Initial treatment of priapism includes aspiration of the corpus cavernosum and intracavernosal vasoconstrictors. In these circumstances, phenylephrine is the most recommended drug because it is safer and with fewer systemic side effects. 6 It was not utilized in the case we describe because it was unavailable in the hospital. In the literature search, treatment strategies adopted were variable. Among the 14 cases described, 10 were managed nonoperatively with aspiration and irrigation of the corpora, and three presented spontaneous remission following medication withdrawal. A shunt procedure was required in five patients. Concerning sexual function, six patients (42.8%) presented sexual dysfunction (four with severe ED and two with incomplete erections) after the episode of priapism, whereas seven persisted sexually functional.
It is estimated that 50% of men older than 60 years have LUTS. 16 The current trend is to do clinical treatment, except when surgery is imperative. 2 As a-blockers are the chief class of drugs in this management, their use is commonplace. Although more cases could be expected, priapism reports continue to be exceedingly rare. A definite explanation Adrenergic a-blockers and priapism SJT Spagnul et al Adrenergic a-blockers and priapism SJT Spagnul et al for this scenario does not exist, but this review demonstrates a trend of occurrence in younger individuals (only one reported patient was more than 60 years old), who have more preserved mechanisms of erection and perhaps are more susceptible. Although this rationale seems to be pertinent, the issue is complex and unsettled, as the authors have not seen cases of priapism following the new common practice of administering a-blockers for patients with distal ureteral calculi.
Conclusion
The a-blockers are safe in the management of LUTS, especially the uroselective drugs that are associated with side effects infrequently. The occurrence of priapism related to this class of drugs is rare and seems to be more frequent when higher doses and nonuroselective agents are used. Despite this, patients should always be informed about this possibility and how to proceed, avoiding substantial morbidity (as we observed in this review) brought by late presentations.
